Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979786 | 0.92 | CYP1A2 (0.55) | L3MBTL1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL11599081 | 0.86 | L3MBTL1 (0.64) | L3MBTL1KMT2AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL31725340 | 0.85 | KMT2A (0.65) | L3MBTL1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8716883 | 0.85 | KMT2A (0.65) | L3MBTL1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13872957 | 0.83 | L3MBTL1 (0.47) | L3MBTL1SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11599074 | 0.81 | L3MBTL1 (0.66) | L3MBTL1KMT2AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL6314811 | 0.80 | GAA (0.51) | KMT2AALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL23885115 | 0.80 | L3MBTL1 (0.60) | L3MBTL1KMT2AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL7079342 | 0.80 | L3MBTL1 (0.60) | L3MBTL1KMT2AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL30254315 | 0.80 | L3MBTL1 (0.60) | L3MBTL1KMT2AALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-20 | — | — | US | disclosed |
| US-8802700-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1409463-B1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1242385-B1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | MORIARTY KEVIN J | 2005-10-27 | — | — | US | disclosed |
| US-6906067-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1409463-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | Bristol-Myers Squibb Company (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003002542-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-09 | — | — | WO | disclosed |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | PHARMACEOPEIA, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1242385-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | PHARMACOPEIA, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2001047897-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, RELA, NFKBIA | L3MBTL1 3895/4885KMT2A 3439/4885ALDH1A1 394/4885 |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | L3MBTL1 3552/4885KMT2A 4245/4885ALDH1A1 2165/4885 |
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | L3MBTL1 3552/4885KMT2A 4245/4885ALDH1A1 2165/4885 |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | L3MBTL1 3659/4885KMT2A 3548/4885ALDH1A1 274/4885 |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | L3MBTL1 3659/4885KMT2A 3548/4885ALDH1A1 274/4885 |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | L3MBTL1 3552/4885KMT2A 4245/4885ALDH1A1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.